- Home
- FATE vs JLS Comparison
FATE vs JLS Comparison
Compare FATE & JLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FATE | JLS |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.8M | 103.4M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | FATE | JLS |
|---|---|---|
| Price | $1.07 | $18.18 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $3.92 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 26.6K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.33% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,137,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.66 | $15.48 |
| 52 Week High | $1.94 | $17.97 |
Technical Indicators
Market Signals| Indicator | FATE | JLS |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 41.00 |
| Support Level | $0.97 | $18.06 |
| Resistance Level | $1.13 | $18.25 |
| Average True Range (ATR) | 0.06 | 0.13 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 63.69 | 28.75 |
Price Performance
Historical ComparisonAbout FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.